Read by QxMD icon Read

(Bladder Cancer) AND Screening

Zhaoju Tian, Shuang Cao, Cheng Li, Mingfang Xu, Huaiqing Wei, Han Yang, Qiyu Sun, Qikui Ren, Le Zhang
PURPOSE: The aim of our study was to validate the sway of long noncoding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) on the metabolism and growth of bladder cancer cells by microRNA-31 (miR-31)/cyclin-dependent kinase 1 ( CDK1). METHODS: The Gene Expression Omnibus database was used for analyzing the differentially expressed lncRNA and messenger RNA (mRNA) in bladder cancer tissues, with the highly expressed lncRNA PVT1 and mRNA CDK1 screened out. The expression level of PVT1 was detected by quantitative reverse-transcription polymerase chain reaction, cell viability by Cell Counting Kit-8 assay, cell proliferation and scratch by 5-bromo-2'-deoxyuridine assay, cell migration and invasion by transwell assays, the expression level of CDK1 by immunohistochemistry and western blot analysis, transcription factor targeting by dual-luciferase assay, and the effect of PVT1 on bladder cancer growth by nude mice tumor formation experiment...
October 14, 2018: Journal of Cellular Physiology
Xin Chen, Rixin Chen, Wen-Su Wei, Yonghong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gangjun Yuan, Siliang Chen, Shen-Jie Guo, Kanghua Xiao, Zhuo-Wei Liu, Jun Hang Luo, Fang-Jian Zhou, Dan Xie
PURPOSE: Circular RNAs (circRNAs), a novel class of non-coding RNAs, have recently been drawn lots of attention in the pathogenesis of human cancers. However, the role of circRNAs in cancer cells epithelial-mesenchymal transition (EMT) remains unclear. In this study, we aimed to identify novel circRNAs that regulates urothelial carcinoma of the bladder (UCB) cells EMT and explored their regulatory mechanisms and clinical significance in UCBs. EXPERIMENTAL DESIGN: We first screened circRNA expression profiles using a circRNA microarray in paired UCB and normal tissues, and then studied the clinical significance of an up-regulated circRNA, circPRMT5, in a large cohort of UCB patients...
October 10, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Su Zhang, Yong-Yan Chang, Yu-Wen Gong, Yan-Jun Gao, Qi Guo, Yu-Han Wang, You-Li Zhao, Zhi-Ping Wang
Chemotherapy is still a standard treatment of unresectable bladder cancer or distant metastases. The chemotherapy resistance always occurs after a period of treatment indicating poor prognosis. The current study aimed to explore the molecular mechanism of chemoresistance in bladder cancer cells. The gene expression profiles of GSE77883, including three untreated T24 cells samples and three gemcitabine-resistant T24 cells samples, was downloaded from Gene Expression Omnibus database. The screening of differentially expressed genes (DEGs), gene function analysis, and interaction prediction between microRNAs (miRNAs) and DEGs were performed by R software...
October 10, 2018: Journal of Cellular Biochemistry
Yin Wang, Mark L Day, Diane M Simeone, Phillip L Palmbos
Bladder cancer is a significant health problem. It is estimated that more than 16,000 people will die this year in the United States from bladder cancer. While 75% of bladder cancers are non-invasive and unlikely to metastasize, about 25% progress to an invasive growth pattern. Up to half of the patients with invasive cancers will develop lethal metastatic relapse. Thus, understanding the mechanism of invasive progression in bladder cancer is crucial to predict patient outcomes and prevent lethal metastases...
September 13, 2018: Journal of Visualized Experiments: JoVE
Taku Murakami, Cindy M Yamamoto, Tomoshige Akino, Hiroshi Tanaka, Nobuyuki Fukuzawa, Hidetaka Suzuki, Takahiro Osawa, Takahiro Tsuji, Toshimori Seki, Hiroshi Harada
Objective: Urinary extracellular vesicles (EV) could be promising biomarkers for urological diseases. In this retrospective feasibility study, we conducted biomarker screening for early stage bladder cancer using EV mRNA analysis. Methods: Biomarker candidates were identified through RNA-seq analysis of urinary EV from patients with non-muscle invasive bladder cancer (N=3), advanced urothelial cancer (N=3), no residual tumor after TURBT (N=2), and healthy and disease controls (N=4)...
August 28, 2018: Oncotarget
Neha Wadhwa, Blessy Baby Mathew, Sumit Tandon, Vinai George Biju, Archana Tiwari
Aims: This study aims to determine the diagnostic efficacy of microsatellite markers for screening bladder cancer in population at high risk. Materials and Methods: A population of 200 people was screened for bladder cancer using a set of microsatellite markers. Urine samples were obtained from four different types of population groups - Group 1 (healthy population group), Group 2 (current smokers with a smoking history of more than 10 years), Group 3 (bladder cancer group), and Group 4 (bladder cancer group who were former smokers with a history of more than 10 years)...
July 2018: Journal of Cancer Research and Therapeutics
K Bowa, C Mulele, J Kachimba, E Manda, V Mapulanga, S Mukosai
Background: Cancer of the bladder is the ninth leading cause of cancer in developed countries. It is the second most common urological malignancy. Transitional cell carcinoma (TCC) is the most common histological subtype in developed countries. In most of Africa, the most common type is squamous cell carcinoma (SCC). Cancer of bladder guidelines produced by the European Urological Association and the American Urological Association, including the tumor, node, and metastasis staging is focused on TCC of the bladder...
July 2018: Annals of African Medicine
Feng Wang, Yanwen Zu, Weiping Huang, Hongde Chen, Hui Xie, Yu Yang
An increasing number of studies have elucidated the essential roles of long noncoding RNAs (lncRNAs) in tumor development. LncRNAs are also closely associated with bladder cancer (BCa) progression. In the present study, we screened out a novel lncRNA CALML3-AS1 with increased expression value in BCa tissues. Particularly, we showed that CALML3-AS1 overexpression correlates with advanced staging and an unsatisfactory prognosis. Functional experiments illustrated that CALML3-AS1 knockdown suppressed BCa cell proliferation, arrested cell-cycle progression and impaired migration and invasion while promoting apoptosis...
September 26, 2018: Biochemical and Biophysical Research Communications
Sanne W Ten Broeke, Heleen M van der Klift, Carli M J Tops, Stefan Aretz, Inge Bernstein, Daniel D Buchanan, Albert de la Chapelle, Gabriel Capella, Mark Clendenning, Christoph Engel, Steven Gallinger, Encarna Gomez Garcia, Jane C Figueiredo, Robert Haile, Heather L Hampel, John L Hopper, Nicoline Hoogerbrugge, Magnus von Knebel Doeberitz, Loic Le Marchand, Tom G W Letteboer, Mark A Jenkins, Annika Lindblom, Noralane M Lindor, Arjen R Mensenkamp, Pål Møller, Polly A Newcomb, Theo A M van Os, Rachel Pearlman, Marta Pineda, Nils Rahner, Egbert J W Redeker, Maran J W Olderode-Berends, Christophe Rosty, Hans K Schackert, Rodney Scott, Leigha Senter, Liesbeth Spruijt, Verena Steinke-Lange, Manon Suerink, Stephen Thibodeau, Yvonne J Vos, Anja Wagner, Ingrid Winship, Frederik J Hes, Hans F A Vasen, Juul T Wijnen, Maartje Nielsen, Aung Ko Win
PURPOSE: Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 variants...
October 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Jennifer Y Ju, Anne M Mills, Mani S Mahadevan, Jinbo Fan, Stephen H Culp, Martha H Thomas, Helen P Cathro
Lynch syndrome (LS) is defined by germline mutations in DNA mismatch repair (MMR) genes, and affected patients are at high risk for multiple cancers. Reflexive testing for MMR protein loss by immunohistochemistry (IHC) is currently only recommended for colorectal and endometrial cancers, although upper tract urothelial carcinoma (UTUC) is the third-most common malignancy in patients with LS. To study the suitability of universal MMR IHC screening for UTUC, we investigated MMR expression and microsatellite status in UTUC in comparison to bladder UC (BUC), and evaluated the clinicopathologic features of UTUC...
November 2018: American Journal of Surgical Pathology
Stefan Garczyk, Ursula Schneider, Isabella Lurje, Katharina Becker, Thomas A Vögeli, Nadine T Gaisa, Ruth Knüchel
Bladder cancer therapy relies on aggressive treatments highlighting the need for new, targeted therapies with reduced side effects. SWI/SNF complexes are mutated in ~20% across human cancers and dependency of SWI/SNF-deficient tumors on EZH2 has been uncovered recently. To systematically dissect the frequency of genetic alterations in SWI/SNF complexes potentially contributing to their inactivation, mutations and copy number variations in 25 SWI/SNF subunit genes were analyzed making use of publicly available sequencing data for 408 muscle-invasive bladder carcinoma samples...
2018: PloS One
Zhun Wu, Wei Huang, Xuegang Wang, Tao Wang, Yuedong Chen, Bin Chen, Rongfu Liu, Peide Bai, Jinchun Xing
BACKGROUND: This study aimed to investigate the effect of over-expressing circular RNA CEP128 (circCEP128) on cell functions and explore the molecular mechanism of which in bladder carcinoma. METHODS: The differentially expressed circRNAs and mRNAs in bladder carcinoma cells and cells in adjacent tissues were screened out using microarray analysis. Expression levels of circRNAs and mRNAs in tissues and cells were determined by qRT-PCR. Expression of SOX11 was detected by western blot...
July 31, 2018: Molecular Medicine
Meiqin Yan, Xuan Jing, Yina Liu, Xiangrong Cui
Bladder cancer (BC) is one of the most common urogenital malignancies. However, present studies of its multiple gene interaction and cellular pathways remain unable to accurately verify the genesis and the development of BC. The aim of the present study was to investigate the genetic signatures of BC and identify its potential molecular mechanisms. The gene expression profiles of GSE31189 were downloaded from the Gene Expression Omnibus database. The GSE31189 dataset contained 92 samples, including 52 BC and 40 non-cancerous urothelial cells...
September 2018: Oncology Letters
Paul Sargos, Brian C Baumann, Libni Eapen, John Christodouleas, Amhit Bahl, Vedang Murthy, Jason Efstathiou, Valérie Fonteyne, Leslie Ballas, Mohamed Zaghloul, Guilhem Roubaud, Mathieu Orré, Stéphane Larré
BACKGROUND: Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic outcomes. We aimed to systematically review evidence regarding factors associated with LRR and to propose a framework for adjuvant radiotherapy (RT) in patients with MIBC...
July 21, 2018: Cancer Treatment Reviews
Liliana Vartolomei, Matteo Ferro, Vincenzo Mirone, Shahrokh F Shariat, Mihai Dorin Vartolomei
Background: Depression affects more than 300 million people of all ages worldwide. In patients with cancer the reported prevalence is up to 24%. Objective: To systematically review the literature to report the prevalence of depression and anxiety among patients with bladder cancer (BC). Methods: Web of Science, MEDLINE/PubMed, and The Cochrane Library were searched between January and March 2018 using the terms "bladder carcinoma OR bladder cancer AND depression OR anxiety"...
July 30, 2018: Bladder Cancer
Mario I Fernández, Maurizio Brausi, Peter E Clark, Michael S Cookson, H Barton Grossman, Makarand Khochikar, Lambertus A Kiemeney, Bernard Malavaud, Rafael Sanchez-Salas, Mark S Soloway, Robert S Svatek, Raghunandan Vikram, Alina Vrieling, Ashish M Kamat
PURPOSE: To update current recommendations on prevention, screening, diagnosis, and evaluation of bladder cancer (BC) based on a thorough assessment of the most recent literature on these topics. METHODS: A non-systematic review was performed, including articles until June 2017. A variety of original articles, reviews, and editorials were selected according to their epidemiologic, demographic, and clinical relevance. Assessment of the level of evidence and grade of recommendations was performed according to the International Consultation on Urological Diseases grading system...
August 13, 2018: World Journal of Urology
Samuel M Cohen
Screening for carcinogens in general, and for the urinary bladder specifically, traditionally involves a two-year bioassay in rodents, the results of which often do not have direct relevance to humans with respect to mode of action (MOA) and/or dose response. My proposal describes a multi-step short-term (90 day) screening process that characterizes known human urinary bladder carcinogens, and identifies those reported in rodent two-year bioassays. The initial step is screening for urothelial proliferation, by microscopy or by increased Ki-67 labeling index...
July 1, 2018: Toxicology Research
Wen-Su Wei, Xin Chen, Li-Yi Guo, Xiang-Dong Li, Ming-Hui Deng, Gang-Jun Yuan, Le-Ye He, Yong-Hong Li, Zhi-Lin Zhang, Li-Juan Jiang, Ri-Xin Chen, Xiao-Dan Ma, Shi Wei, Ning-Fang Ma, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, Dan Xie
Clinically, most of human urothelial carcinoma of the bladder (UCB)-related deaths result from tumor metastasis, but the underlying molecular mechanisms are largely unknown. Recently, a growing number of tripartite motif (TRIM) family members have been suggested to be important regulators for tumorigenesis. However, the impact of most TRIM members on UCB pathogenesis is unclear. In this study, TRIM65 was first screened as an important oncogenic factor of UCB from the Cancer Genome Atlas (TCGA) database and was validated by a large cohort of clinical UCB tissues...
October 28, 2018: Cancer Letters
Joaquim Bellmunt
The rapid development of the cancer stem cells (CSC) field, together with powerful genome-wide screening techniques, have provided the basis for the development of future alternative and reliable therapies aimed at targeting tumor-initiating cell populations. Urothelial bladder cancer stem cells (BCSCs) that were identified for the first time in 2009 are heterogenous and originate from multiple cell types; including urothelial stem cells and differentiated cell types-basal, intermediate stratum and umbrella cells Some studies hypothesize that BCSCs do not necessarily arise from normal stem cells but might derive from differentiated progenies following mutational insults and acquisition of tumorigenic properties...
August 2, 2018: Biomedicines
Matthew E Larson, Perry J Pickhardt
PURPOSE: To compare the rates of colorectal and extracolonic findings at CT colonography (CTC) screening between patients with and without a personal prior history of other. METHODS: Over a 160-month interval, 349 adults (mean age, 60.3 years; 67% female) with a positive history of extracolonic cancer [Ca(+)], excluding 271 patients with isolated non-melanoma skin cancers, underwent CTC screening. This study cohort was compared against 8859 controls (mean age, 57...
July 31, 2018: Abdominal Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"